Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature

Journal of Medical Case Reports

Munehiro Yokoyama³  Atsuo Nakajima²  Tatsuyuki Hayashi¹  Satoru Kawachi²  Jumi Nakata²  Katsuhiro Makino² 

[1] Department of Hematology, Tokyo Metropolitan Police Hospital, 4-22-1 Nakano, Nakano-ku, Tokyo 164-8541, Japan;Department of General Medicine, Tokyo Metropolitan Police Hospital, 4-22-1 Nakano, Nakano-ku, Tokyo 164-8541, Japan;Department of Diagnostic Pathology, Tokyo Metropolitan Police Hospital, 4-22-1 Nakano, Nakano-ku, Tokyo 164-8541, Japan

关键词: Diffuse large-cell lymphoma;    R-CHOP;    Systemic inflammatory response syndrome;    Cytokine release syndrome;    CD20 antibody;    Rituximab;   

Others  :  824753
DOI  :  10.1186/1752-1947-7-280

 received in 2013-05-02, accepted in 2013-09-30,  发布年份 2013

【 摘 要 】

Introduction

Intravascular large B-cell lymphoma is a rare aggressive disseminated disease characterized by the presence of lymphoma cells in small vessels without lymphadenopathy. Rituximab, a novel monoclonal antibody against the CD20 B-cell antigen, has been reported to be effective in treating intravascular large B-cell lymphoma. However, adverse events have been reported in association with rituximab infusion.

Case presentation

We report the case of a 54-year-old Japanese man diagnosed with Asian variant intravascular large B-cell lymphoma who died within five hours of the initiation of a first course of chemotherapy including rituximab. Autopsy results suggested that the patient died of severe systemic inflammatory response syndrome. A literature review revealed that rituximab administered during the second course of chemotherapy (instead of during the first course) appears to reduce the incidence of infusion reactions (from 48% to 15%) without altering the frequency of complete remission outcomes.

Conclusions

Our data indicate that the incidence of adverse reactions to rituximab can be markedly decreased if the tumor load is first reduced with an initial course of chemotherapy excluding rituximab. Future prospective studies of the timing of rituximab administration are warranted.

【 授权许可】

   
2013 Makino et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Shimada K, Kosugi H, Narimatsu H, Shimada S, Suzuki T, Ito M, Kinoshita T, Mori N, Naoe T: Sustained remission after rituximab-containing chemotherapy for intravascular large B-cell lymphoma. J Clin Exp Hematop 2008, 48:25-28.
• [2]Murase T, Yamaguchi M, Suzuki R, Okamoto M, Sato Y, Tamaru J, Kojima M, Miura I, Mori N, Yoshino T, Nakamura S: Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood 2007, 109:478-485.
• [3]Shimada K, Matsue K, Yamamoto K, Murase T, Ichikawa N, Okamoto M, Niitsu N, Kosugi H, Tsukamoto N, Miwa H, Asaoku H, Kikuchi A, Matsumoto M, Saburi Y, Masaki Y, Yamaguchi M, Nakamura S, Naoe T, Kinoshita T: Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol 2008, 26:3189-3195.
• [4]Onrust SV, Lamb HM, Balfour JA: Rituximab. Drugs 1999, 58:79-88. discussion 9-90
• [5]Kulkarni HS, Kasi PM: Rituximab and cytokine release syndrome. Case Rep Oncol 2012, 5:134-141.
• [6]Wu SJ, Chou WC, Ko BS, Tien HF: Severe pulmonary complications after initial treatment with rituximab for the Asian-variant of intravascular lymphoma. Haematologica 2007, 92:141-142.
• [7]Lim LC, Koh LP, Tan P: Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia. J Clin Oncol 1999, 17:1962-1963.
• [8]Seifert G, Reindl T, Lobitz S, Seeger K, Henze G: Fatal course after administration of rituximab in a boy with relapsed all: a case report and review of literature. Haematologica 2006, 91(6 Suppl):ECR23.
• [9]Kasi PM, Tawbi HA, Oddis CV, Kulkarni HS: Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective. Crit Care 2012, 16:231. BioMed Central Full Text
• [10]Sabattini E, Bacci F, Sagramoso C, Pileri SA: WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 2010, 102:83-87.
• [11]Maggi E, Vultaggio A, Matucci A: Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol 2011, 7:55-63.
• [12]Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, Sipe MA, Donegan S, White CA: Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 1999, 17:791-795.
• [13]Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C, Rosenberg J, Levy R: IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997, 15:3266-3274.
• [14]Aoyama T, Sekiguchi Y, Yako T, Sakai K, Hongo K, Tojo K, Ikeda S, Nakayama J, Uehehara T: Recurrent cerebral infarctions caused by intravascular lymphoma diagnosed by brain biopsy: a case report. Jpn J Neurosurg (Tokyo) 2012, 21:342-347.
• [15]Imahashi Y, Ueji T, Shinmura N, Nabeya D, Fujiwara H: A case of intravascular large B-cell lymphoma diagnosed by repeated transbronchial lung biopsy. Ann Jpn Respir Soc 2012, 1:162-164.
• [16]Kaku N, Seki M, Doi S, Hayashi T, Imanishi D, Imamura Y, Imamura Y, Kurihara S, Miyazaki T, Izumikawa K, Kakeya H, Yamamoto Y, Yanagihara K, Tashiro T, Kohno S: A case of intravascular large B-cell lymphoma (IVLBCL) with no abnormal findings on chest computed tomography diagnosed by random transbronchial lung biopsy. Intern Med 2010, 49:2697-2701.
• [17]Ishizuka J, Ito T, Onishi T, Ueda Y: Intravascular large B-cell lymphoma with huge hepatosplenomegaly. Kurashiki Cyuo Byoin Nenpou 2009, 72:247-250.
• [18]Iwagami Y, Sumitani M, Imahashi Y, Kiyota H, Kawano Y, Takifuji N, Takeda K, Kashii T: [A case of intravascular lymphomatosis with no abnormal findings on chest computed tomography and with diffuse pulmonary uptake of 67Ga on scintigraphy]. J Jpn Respir Soc 2006, 44:923-927.
• [19]Kashizaki F, Tamura A, Teramoto S, Kurosaki Y, Komiya K, Kawashima M, Yamane A, Hebisawa A, Nakajima Y: A case of diffuse large B-cell lymphoma with intravascular lymphoma pattern was diagnosed by transbronchial lung biopsy. Nihon Kyobu Rinsyo 2010, 69:665-671.
• [20]Kobayashi K, Kayano S, Yokoyama T, Inoue T, Ikeda N, Suzuki H: A case of intravascular lymphoma with kidney enlargement diagnosed by renal biopsy. Rinsho To Kenkyu 2007, 84:1680-1686.
• [21]Kotake T, Takamori H, Kuwayama M, Hattori H, Takeda M, Takagi K, Karasuno T: [Definitive diagnosis of intravascular large B-cell lymphoma by random skin biopsy]. Canc Chemother 2011, 38:1361-1364.
• [22]Nakano M, Takahashi H, Nikaido T, Aizawa O, Ikegami M, Lu W, Furusato M, Hano H: A case of intravascular large B-cell lymphoma of the spleen. Shindanbyori 2005, 22:121-124.
• [23]Ohkubo H, Yoshida T, Ohta K, Takaku T, Katagiri T, Paku J, Kasuga I, Minemura K, Gotoh A, Serizawa H, Mukai K, Ohyashiki K: [A case of pulmonary intravascular lymphoma treated with CHOP chemotherapy plus rituximab]. Canc Chemother 2005, 32:553-556.
• [24]Okachi S, Matsumoto S, Kojima E, Takada K, Iwata S: Two cases of intravascular lymphoma diagnosed by transbronchial lung biopsy. J Jpn Soc Respir Endosc 2011, 33:469-474.
• [25]Sakurai A, Tomii K, Haruna A, Katakami N, Takahashi Y, Imai Y: [Two cases of successfully treated intravascular lymphoma presenting with fever and dyspnea]. J Jpn Respir Soc 2011, 49:743-749.
• [26]Sawa N, Ubara Y, Katori H, Hoshino J, Suwabe T, Tagami T, Takemoto F, Miyakoshi S, Taniguchi S, Ohashi K, Takaichi K: Renal intravascular large B-cell lymphoma localized only within peritubular capillaries. Report of a case. Intern Med 2007, 46:657-662.
• [27]Shimizu I, Ichikawa N, Yotsumoto M, Sumi M, Ueno M, Kobayashi H: Asian variant of intravascular lymphoma: aspects of diagnosis and the role of rituximab. Intern Med 2007, 46:1381-1386.
• [28]Shinoda H, Maejima A, Shimizu K, Onaka A, Boku T, Oyamada Y: [A case of intravascular lymphoma with diffuse centrilobular opacities]. J Jpn Respir Soc 2010, 48:76-80.
• [29]Suzuki K, Naito Y, Ino K, Kobayashi K, Sekine T: A case of pulmonary intravascular B-cell lymphoma with liver cirrhosis treated with combination chemotherapy with rituximab. Naika 2007, 100:992-995.
• [30]Tadokoro J, Arai Y, Tokita K, Iso H, Nakamura Y, Maki K, Sasaki K, Mitani K: [Asian variant of intravascular large B-cell lymphoma diagnosed by bone marrow biopsy]. Rinsho Ketsueki 2007, 48:61-63.
• [31]Takahashi R, Nishikawa M, Nomi F, Kusano N, Kakemizu N, Ishigatsubo Y: [Case of intravascular lymphoma diagnosed by transbronchial lung biopsy, with transient spontaneous remission]. J Jpn Respir Soc 2010, 48:825-830.
• [32]Takizawa S, Shirasugi Y, Nakamura N, Nakagawa S, Tsuchiya T, Ando K, Takagi S: An atypical form of Asian variant of intravascular large B-cell lymphoma presenting with myelopathy alone for 4 months prior to pancytopenia. Intern Med 2007, 46:1879-1880.
• [33]Tanikawa M, Aihara N, Inagaki H, Yamada K: A case of intravascular large B-cell lymphoma, suspected multiple cerebral lacunar infarctions at first. Bunshinoukekkanbyo 2009, 8:116-120.
• [34]Wakamatsu K, Komori M, Nagata N, Kumazoe H, Kajiki A, Kitahara Y: [Two cases of intravascular lymphomatosis diagnosed by transbronchial lung biopsy]. J Jpn Respir Soc 2009, 47:875-880.
• [35]Watanabe W, Shimizu Y, Osada H, Okada T, Ohno H, Nakada K, Yanagita H, Honda N, Toyozumi Y, Tamaru J, Itoyama S: A case of pulmonary intravascular lymphomatosis. Dansoueizoukenkyukaizasshi 2010, 37:1-5.
• [36]Hannawa IS, Bestul DJ: Rituximab tolerability when given before or after CHOP. J Oncol Pharm Pract 2011, 17:381-386.